Alcon (ALC) Receives a Sell from Kepler Capital

In a report issued on February 16, David Evans from Kepler Capital maintained a Sell rating on Alcon (ALCResearch Report), with a price target of CHF64.00. The company’s shares closed last Thursday at $77.45.

According to TipRanks.com, Evans is ranked #2867 out of 7805 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $86.55 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $88.78 and a one-year low of $65.60. Currently, Alcon has an average volume of 726.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More